Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
LAVA Therapeutics (LVTX)
NASDAQ:LVTX
LAVA Therapeutics (LVTX) Stock Price & Analysis
152 Followers
LVTX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.13 - $6.47
Previous Close$2.06
Volume33.70K
Average Volume (3M)81.19K
Market Cap
$54.16M
Enterprise Value-$35.10M
Total Cash (Recent Filing)$95.57M
Total Debt (Recent Filing)$6.31M
Price to Earnings (P/E)―
Beta0.47
Next Earnings
Aug 12, 2024EPS Estimate
-$0.33Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.08
Shares Outstanding26,289,087
10 Day Avg. Volume72,411
30 Day Avg. Volume81,193
Standard Deviation0.28
R-Squared0.01
Alpha-0.02
Financial Highlights & Ratios
Price to Book (P/B)0.96
Price to Sales (P/S)7.22
Price to Cash Flow (P/CF)-1.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-2.23
Enterprise Value/Gross Profit-10.68
Enterprise Value/Ebitda3.93
Forecast
1Y Price Target
$6.00Price Target Upside191.26% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
LAVA Therapeutics News
PremiumCompany Announcements
LAVA Therapeutics Shareholders Approve Key Resolutions
PremiumPress Releases
LAVA Announces Annual Meeting of Shareholders
PremiumCompany Announcements
LAVA Therapeutics’ Innovative Gammabody® Cancer Therapy
PremiumCompany Announcements
LAVA Therapeutics Narrows Losses, Grows Profit
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentLAVA-1207 demonstrated favorable safety and early signs of clinical activity in refractory prostate cancer patients.
Financial PerformanceLava Therapeutics reported a better than expected financial performance with revenue of $353,000 and lower R&D and SG&A expenses.
PartnershipsPfizer and Janssen are both moving partnered assets forward, indicating strong collaboration and support.
Bears Say
Clinical TrialsThe risk of being first to explore the dose / activity relationship for Vγ9Vδ2 TCE is high.
Safety ConcernsThree dose-limiting toxicities in the LAVA-1207 and IL-2 combination arm indicate potential safety concerns.
Therapy EfficacyContinued enrollment to the cohort combining with low-dose IL-2 indicates a potential deficit in monotherapy activity.
---
Ownership Overview
0.00%
Insiders
2.98% Mutual Funds
<0.01% Other Institutional Investors
97.02% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
LVTX FAQ
What was LAVA Therapeutics’s price range in the past 12 months?
LAVA Therapeutics lowest stock price was $1.13 and its highest was $6.47 in the past 12 months.
What is LAVA Therapeutics’s market cap?
Currently, no data Available
When is LAVA Therapeutics’s upcoming earnings report date?
LAVA Therapeutics’s upcoming earnings report date is Aug 12, 2024 which is in 21 days.
How were LAVA Therapeutics’s earnings last quarter?
LAVA Therapeutics released its earnings results on May 21, 2024. The company reported -$0.02 earnings per share for the quarter, beating the consensus estimate of -$0.22 by $0.2.
Is LAVA Therapeutics overvalued?
According to Wall Street analysts LAVA Therapeutics’s price is currently Undervalued.
Does LAVA Therapeutics pay dividends?
LAVA Therapeutics does not currently pay dividends.
What is LAVA Therapeutics’s EPS estimate?
LAVA Therapeutics’s EPS estimate is -$0.33.
How many shares outstanding does LAVA Therapeutics have?
LAVA Therapeutics has 26,292,187 shares outstanding.
What happened to LAVA Therapeutics’s price movement after its last earnings report?
LAVA Therapeutics reported an EPS of -$0.02 in its last earnings report, beating expectations of -$0.22. Following the earnings report the stock price went down -1.852%.
Which hedge fund is a major shareholder of LAVA Therapeutics?
Among the largest hedge funds holding LAVA Therapeutics’s share is Bruce & Co., Inc.. It holds LAVA Therapeutics’s shares valued at 3M.
---
LAVA Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$6.00 (191.26% Upside)
$6.00 (191.26% Upside)
Crowd Wisdom
Very Positive
Last 7 Days ▲ 8.8%
Last 30 Days ▲ 13.3%
Last 30 Days ▲ 13.3%
Technicals
SMA
Negative
20 days / 200 days
Momentum
0.48%
12-Months-Change
Fundamentals
Return on Equity
-45.40%
Trailing 12-Months
Asset Growth
-26.76%
Trailing 12-Months
Company Description
LAVA Therapeutics
LAVA Therapeutics NV is a biotechnology company. It is focused on transforming cancer treatment by developing a platform of novel bispecific antibodies designed to selectively induce gamma-delta T cell-mediated immunity against tumor cells.
---
LVTX Stock 12 Month Forecast
Average Price Target
$6.00
▲(191.26% Upside)
Technical Analysis
Best Analysts Covering LVTX
1 Year
1 Year Success Rate
5/10 ratings generated profit
1 Year Average Return
-8.42%
reiterated a buy rating 24 days ago
Copying Arthur He CFA's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of -8.42% per trade.
---